Kang X.-Z.Guo X.-R.Chen B.-B.Zhang T.-Y.Yuan Q.PEI-JER CHENZhang J.Xia N.-S.2021-07-032021-07-0320182164-5515https://www.scopus.com/inward/record.uri?eid=2-s2.0-85045233378&doi=10.1080%2f21645515.2018.1449553&partnerID=40&md5=a48d15491906d42ace63a036c2ddbceehttps://scholars.lib.ntu.edu.tw/handle/123456789/568336[SDGs]SDG3aflatoxin; carcinogen; den; hepatitis B antibody; hepatitis B surface antigen; immunoglobulin G; unclassified drug; immunoglobulin; animal experiment; animal model; cancer incidence; carcinogenesis; clinical evaluation; hepatitis B; Hepatitis B virus; immunosuppressive treatment; Letter; liver carcinogenesis; liver tumor; mouse; nonhuman; nuclear magnetic resonance imaging; transgenic mouse; tumor volume; viremia; animal; Hepatitis B virus; immunology; liver cell carcinoma; liver tumor; male; viremia; virology; Animals; Carcinogenesis; Carcinoma, Hepatocellular; Hepatitis B virus; Immunoglobulins; Liver Neoplasms; Male; Mice; Mice, Transgenic; Viremialetter10.1080/21645515.2018.1449553295331342-s2.0-85045233378